Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of cabazitaxel in urothelial transitional cell carcinoma after platinum therapy
2011-003498-27Phase 2Terminated
- Sponsor
- SOGUG
- Start
- Oct 2011
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabazitaxel in transitional cell carcinoma (TCC), Renal pelvis urothelial carcinoma (UTUC) and ureteral urothelial carcinoma, sponsored by SOGUG. Primary endpoint: Objective response rate. Started Oct 2011; status: terminated.
02
Drugs
cabazitaxel
03
Conditions
transitional cell carcinoma (TCC)Renal pelvis urothelial carcinoma (UTUC)ureteral urothelial carcinoma
Beyond the preview
Go deeper on 2011-003498-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003498-27.